Table 3 Univariate analyses of various clinicopathological parameters in relation to survival of patients with bladder cancer
From: Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer
Clinical features | N | OS | PFS | ||
|---|---|---|---|---|---|
3-year survival (%) | P | 3-year survival (%) | P | ||
Sex | |||||
Male | 87 | 34 (39.1) | 0.08 | 24 (27.6) | 0.08 |
Female | 39 | 22 (56.4) | 18 (46.2) | ||
Age (years) | |||||
≤70 | 55 | 20 (36.4) | 0.1 | 13 (23.6) | 0.1 |
>70 | 71 | 36 (50.7) | 29 (40.8) | ||
Stage | |||||
Ta | 48 | 30 (62.5) | 0.006 | 26 (54.2) | 0.008 |
T1 | 46 | 22 (47.8) | 12 (26.1) | ||
≥T2 | 32 | 4 (12.5) | 4 (12.5) | ||
Grade | |||||
LMP | 32 | 18 (56.2) | 0.02 | 17 (53.1) | 0.03 |
LG | 43 | 21 (48.8) | 15 (34.9) | ||
HG | 51 | 17 (33.3) | 10 (19.6) | ||
Carcinoma in situ | |||||
Yes | 26 | 16 (61.5) | 0.01 | 12 (46.2) | 0.02 |
No | 100 | 40 (40.0) | 30 (30.0) | ||
miR-100 | |||||
High | 48 | 33 (68.8) | <0.001 | 26 (54.2) | 0.001 |
Low | 78 | 23 (29.5) | 16 (20.5) | ||